Skip to content
Open access

KRAS Expression Complements Genomic Profiling in Identifying Therapeutic Vulnerability in Gastric Cancer.

Sep 2026 · Biomedical Journal · pp. 101036 · 0 citations · 50 references
Medicine

Abstract

Background

Gastric cancer (GC) remains a major therapeutic challenge. Although alterations in the RAS pathway occur in over 50% of tumors, only a limited proportion are clinically actionable. We investigated whether KRAS expression complements genomic profiling for patient stratification and therapeutic vulnerability in GC.

Methods

Comprehensive genomic profiling was performed in 19 Taiwanese GC patients and compared with TCGA-STAD data (n = 434). KRAS mRNA expression and overall survival were evaluated by meta-analysis of 13 independent cohorts (n = 2,521). Protein-level validation was performed by immunohistochemistry in an independent cohort (n = 121). Functional KRAS dependency and response to combined MEK/SHP2 inhibition were assessed in eight GC cell lines.

Results

KRAS amplification was entirely contained within the KRAS-high population, whereas most KRAS-high tumors lacked detectable amplification. High KRAS expression was associated with poorer overall survival (HR 1.23, p = 0.001) and remained an independent prognostic factor after multivariable adjustment (adjusted HR 1.24, p = 0.003). Protein-level analysis showed a concordant trend. KRAS expression correlated strongly with functional dependency (R2 = 0.88, p = 0.005), was enriched in MSI and CIN subtypes, and identified cell lines with enhanced sensitivity to combined MEK/SHP2 inhibition.

Conclusions

KRAS expression complements genomic profiling by identifying biologically relevant KRAS-dependent GCs beyond mutation or amplification alone. Integrating expression-based stratification with genomic profiling may improve patient selection for RAS pathway-directed combination therapies.

Read PDF

Similar papers

Open access Sep 2026

Oncogene-driven genomic profiles are linked to poor overall survival in muscle-invasive bladder cancer (MIBC)

It is suggested that oncogene amplifications, rather than traditional genomic instability metrics, are associated with poor overall survival in MIBC, warranting validation in larger cohorts to assess their potential relevance as prognostic markers and therapeutic targets.

C. Poyet, A. S. Franzen, U. Bieri et al. · 0 citations
Open access Sep 2026

Real world genomic profiling in non-small cell lung cancer reveals regional variations with clinical implications

Routine genomic profiling in NSCLC provides clinically relevant information beyond actionable driver detection when interpreted together with stage, smoking history, age, sex, and regional molecular context, and support a more context-aware interpretation of routine molecular diagnostics in thoracic oncology.

N. Karlowatz, L. Kohn, C. Patthey et al. · 0 citations
Review Oct 2026

Targeting RAS in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies, and activating KRAS mutations occur in more than 90% of tumors. Direct RAS targeting has moved from proof of concept to randomized clinical benefit: in previously treated metastatic PDAC, daraxonrasib improved median overall survival, p...

F. Petrelli, L. Dottorini, A. Zaniboni · 0 citations
Open access Aug 2026

Influence of tumor mutational burden and immune infiltration on cervical squamous cell carcinoma prognosis

Although the clinical utility of the TMBRS is currently moderate, this research provides a critical proof of concept for the interplay among PTGS2, mutational load, and the tumor microenvironment, offering valuable mechanistic insights for future large-scale prospective clinical trials.

Batchimeg Tsedenbal, B. Chimeddorj, Shu-Tao Tan et al. · 0 citations
Open access Aug 2026

Genomic subtypes inferred from clinical sequencing provide significant prognostic stratification in metastatic breast cancer

IntClust can be inferred from routine clinical sequencing and resolves survival heterogeneity not captured by ER or HER2, and reveals subtype-specific contexts for prognostic effects of the same mutation drivers, and for acquisition of ESR1 mutations.

A. Yaacov, A. Grinshpun, P. Pharoah et al. · 0 citations
Sep 2026

A KRAS-ERK-associated model for molecular stratification and prognosis prediction: Highlighting the tumorigenic role of ARNTL2 in KRAS-mutant pancreatic cancer.

A comprehensive analysis of molecular stratification based on KRAS-ERK-associated genes and established a five-gene KRAS-ERK prognosis signature (KEPS), establishing KEPS as a novel molecular tool for risk stratification in KRAS-mutant pancreatic cancer and highlighting that ARNTL2 may represent a potential personalize...

Wei-Hao Lin, Chun-Gui Xu, Chao-Qun Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.